Selank has been studied across validated paradigms like the forced swimming test in BALB/c mice and depressive-like readouts in WAG/Rij rats. Researchers track immobility, sucrose preference, and locomotor activity to confirm anxiolysis isn’t just stimulation. Mechanistically, Selank modulates GABA receptors through subtype-selective positive allosteric action, inhibits enkephalinase (IC50 ~15 µM), and engages dopaminergic and opioid systems. Naloxone and apomorphine probes reveal these links. The dose-dependent patterns uncover something worth knowing.
Key Takeaways
- Selank’s anxiolytic activity is validated using paradigms like the forced swimming test in BALB/c mice and depressive-like models in WAG/Rij rats.
- Low single doses reduced immobility in BALB/c mice, while repeated or higher doses weakened this forced swimming effect.
- Locomotor assays confirmed Selank’s anxiolysis was not driven by stimulation, as it did not substantially alter activity in WAG/Rij rats.
- Mechanistic probes linked Selank’s effects to GABAergic and opioid systems, with naloxone blocking one dopaminergic effect.
- Selank inhibits enkephalin hydrolysis (IC50 ~15 µM) and acts as a subtype-selective positive allosteric modulator of GABA receptors, distinct from benzodiazepines.
How is Selank studied in anxiolytic research models
Researchers study Selank’s anxiolytic activity using validated behavioral paradigms in mice and rats. In BALB/c mice, they measure immobility in the forced swimming test, finding low single doses reduce it while repeated or higher doses weaken the effect. They test depressive-like signs in WAG/Rij rats, where repeated high-dose Selank counters increased immobility and reduced sucrose preference. They track locomotor activity to confirm anxiolysis isn’t just stimulation. Selank doesn’t substantially alter it in the WAG/Rij model. They probe dopaminergic function using apomorphine-induced testing, where Selank reduces hyperfunction manifestations, and they apply naloxone to expose opioid-system involvement. Alongside behavior, they run receptor-binding and enzyme assays, quantifying GABA modulation and enkephalinase inhibition to link mechanism with observed anti-anxiety outcomes.
What are anxiolytic research models
Anxiolytic research models are standardized experimental paradigms used to provoke, measure, and quantify anxiety-like and depressive-like behavior, letting researchers test whether a compound like Selank actually reduces it. You rely on reproducible behavioral readouts, correlating observable changes with underlying receptor mechanisms like GABA modulation and enkephalinase inhibition. These paradigms let you separate genuine anxiolysis from confounds like sedation or locomotor suppression.
Here’s what you’re typically working with:
- Forced swimming test, measuring immobility as a depressive-like signal in BALB/c mice.
- WAG/Rij rats, a genetic depression model tracking immobility and sucrose preference.
- Apomorphine-induced testing, probing dopaminergic hyperfunction.
- Locomotor activity assays, confirming effects aren’t just stimulation.
Each model isolates a distinct behavioral and mechanistic dimension for you.
What mechanisms does Selank act on in studies
Selank appears to act mainly through GABAergic and opioid-linked mechanisms in studies. The dominant proposed mechanism is positive allosteric modulation of GABA receptors, described in review-level literature as subtype-selective and concentration-dependent. This action differs from direct benzodiazepine-like receptor activation, and when you combine Selank with benzodiazepines, you see non-cumulative, distinct modulation of GABA binding. Researchers repeatedly link this GABAergic action to the peptide’s anti-anxiety effect. A second pathway involves enkephalinase inhibition: Selank dose-dependently blocked plasma enkephalin hydrolysis with an IC50 of 15 microM, outperforming bacitracin and puromycin. Opioid-system involvement shows up too, since naloxone blocked one of Selank’s dopaminergic effects. Together, these findings point toward GABAergic and opioid-linked mechanisms driving anxiolysis.
How does Selank affect neurotransmitter systems in research
Selank affects neurotransmitter systems in research by modulating GABAergic, opioid, and dopaminergic pathways. It appears to influence receptors and enzymes rather than flooding a single target. Selank neuroactive research has revealed potential therapeutic applications for anxiety and depression. These findings suggest that Selank could offer a new approach to mental health treatment by targeting multiple neurotransmitter systems.
- GABA receptors: Selank acts as a subtype-selective, concentration-dependent positive allosteric modulator, distinct from benzodiazepine-like activation.
- Enkephalin handling: It inhibits plasma enkephalin hydrolysis with an IC50 near 15 microM, outperforming bacitracin and puromycin in that assay.
- Opioid involvement: Naloxone blocks one of Selank’s dopaminergic effects, implicating opioid signaling.
- Dopaminergic tone: In apomorphine-induced testing, Selank reduces manifestations of dopaminergic hyperfunction in mice.
Combined with benzodiazepines, Selank shows non-cumulative, distinct modulation of GABA binding, linking these mechanisms to anxiolysis.
Which endpoints do Selank studies measure
Selank studies measure behavioral, biochemical, and human clinical endpoints downstream of GABAergic, opioid, and dopaminergic targets. Behavioral endpoints dominate: anxiety-like behavior across multiple paradigms, immobility in the forced swimming test, and sucrose intake or preference as depressive-like markers. Locomotor activity is also measured as a control, confirming effects aren’t stimulation artifacts.
| Endpoint Type | Specific Measure |
|---|---|
| Behavioral anxiety | Anxiety-like behavior, apomorphine response |
| Depressive-like signs | Immobility, sucrose preference |
| Biochemical | Enkephalin hydrolysis (IC50 15 µM) |
At the molecular level, plasma enkephalin hydrolysis is measured and GABA-binding modulation. Human studies quantify anxiolytic strength versus phenazepam, antiasthenic and psychostimulant effects, plus quality-of-life ratings persisting roughly one week post-dose. Kisspeptin-10 and GnRH signaling play crucial roles in the regulation of reproductive hormones. Disturbances in these signaling pathways can lead to significant reproductive disorders.
What are the limitations of current research
Current research is limited by a small, regionally concentrated clinical evidence base that has not matched the scale or rigor of the mechanistic findings. The receptor-level data, including subtype-selective GABA modulation, enkephalinase inhibition at IC50 15 microM, and naloxone-blockable dopaminergic effects, remain stronger than the available human evidence. The kisspeptin study design aims to bridge the gap between mechanistic insights and clinical applicability. By focusing on broader participant demographics, researchers hope to generate more robust data that reflects diverse populations.
Key limitations include:
- No large-scale Western randomized controlled trials validating the anxiolytic and nootropic signals.
- Small study samples, largely limited to comparisons against phenazepam.
- Regionally concentrated publications, restricting independent replication of GABA and opioid mechanisms.
- Short follow-up windows, with the roughly one-week post-dose effect underexplored.
Shop Nootropic Research Peptides at Holas
Anxiolytic and neuroactive research demands peptides with verified quality and reliable purity documentation. Holas supplies laboratory-grade research peptides, third-party tested and shipped under sterile handling standards for research use. Browse our shop or contact us to source what you need for your work
Frequently Asked Questions
What Is Selank’s Peptide Sequence and Chemical Structure?
Selank’s sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic heptapeptide studied for anxiolytic activity in research models. It comprises seven linked amino acids: threonine, lysine, proline, arginine, proline, glycine, and proline. The structure derives from tuftsin, extended to improve stability. This defined sequence underpins the GABA-modulating and enkephalinase-inhibiting mechanisms described in the research literature.
How Long Does Selank’s Anxiolytic Effect Last in Studies?
In a comparative clinical study versus phenazepam, Selank’s anxiolytic effect was reported to persist about one week after the final dose, a notably prolonged action for a heptapeptide. Research attributes this to its proposed mechanism: subtype-selective, concentration-dependent positive allosteric modulation of GABA receptors, distinct from benzodiazepine-like activation. The reported effect was accompanied by mild nootropic activity, though the evidence base for this duration remains small and regionally concentrated.
How Does Selank Compare to Phenazepam in Research?
In a comparative clinical study, Selank was reported to match phenazepam’s anxiolytic strength while showing a different liability profile. The study described anxiolysis alongside mild nootropic activity and did not report the classic adverse effects associated with phenazepam. The overall evidence base remains small and regionally concentrated, and these are research observations rather than evidence of any approved use.
Does Selank Affect Sedation or Locomotor Activity in Models?
Research does not report substantial sedation with Selank. In the WAG/Rij rat model, it did not meaningfully alter general locomotor activity, indicating its anxiolytic profile in that model is not explained by simple stimulation or sedation. This is consistent with its proposed mechanism of subtype-selective, concentration-dependent positive allosteric modulation of GABA receptors, distinct from direct benzodiazepine-like activation. Cited studies describe no classic anxiolytic adverse effects.
Are There Large-Scale Western Clinical Trials on Selank?
No, there are no large-scale Western randomized controlled trials on Selank. The published evidence base is small and regionally concentrated, drawing mostly from Russian animal studies and limited clinical research. Comparative data against phenazepam describe anxiolytic and mild nootropic activity, but the scale does not match established anxiolytics. The compound remains mechanistically studied rather than broadly validated.
